Inventory of new drug approvals in the past 5 years: Novartis has the most revenue, Roche, Eli Lilly, and AbbVie have the most revenue

New drug approval is the holy grail of pharmaceutical companies large and small, but a series of nods from the regulatory authorities cannot automatically translate into optimal performance

Vantage, a subsidiary of Evaluate, a life sciences industry market consulting company, pointed out in a recent report that in the past five years, the world's top 11 pharmaceutical companies have introduced 76 new drugs to the market

At the same time, Roche, Eli Lilly, and AbbVie seem to get the most benefits from the newly launched products, thanks to the advent of some new products that have reached or are about to reach blockbuster status, such as Roche and Eli Lilly’s respective anti-cancer products.

According to the annual report released by Roche, the company Tecentriq generated 2.

It should be noted that Evaluate’s analysis only covers projects owned by these companies at the time of regulatory approval, and does not consider the impact of drugs acquired by these companies after regulatory approval, even if this is a “legal way” to conduct products.

The report also pointed out that the first approval of new drugs is only part of the R&D strategy of pharmaceutical companies, and it is also very important to expand the use of existing drugs, especially in the fields of cancer and immunology, which is a popular strategy

In addition to Novartis and BMS at the two ends, the pharmaceutical companies in the middle: Merck and Roche both tied for second with 9 new drug approvals, Eli Lilly ranked third with 8 new drug approvals, and Pfizer and GlaxoSmithKline each had 7 Sanofi has 6 models, while AbbVie, Johnson & Johnson and AstraZeneca each have 5 models

65% of Roche’s net present value of US$217.

According to the same standard, GSK "performed not badly in this analysis.

As stated in a report released by investment bank SVB Leerink analyst Geoffrey Porges earlier this year, GSK and its leadership have come under fire in recent months due to a series of "serial" R&D setbacks

Reference source:

1.